EGFR and anemia (phenotype): Compared with EGFR TKIs and monotherapy, the patients who received synchronous combination therapy presented with a significant increase in the incidence of grade 3/4 anemia and fatigue (anemia: RR = 6.71, 95%CI = 1.25–35.93, P = 0.026; fatigue: RR = 9.60, 95%CI = 2.28–40.86, P = 0.002).